Особливості перебігу симптомів нижніх сечових шляхів у чоловіків із доброякісною гіперплазією передміхурової залози та COVID-19
TLDR COVID-19 worsens urinary symptoms in men with benign prostatic hyperplasia, requiring careful treatment management.
The document discussed the impact of COVID-19 on the management of benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) in men. During the pandemic, there was a consensus to minimize invasive treatments to protect medical personnel, leading to an increase in emergency urological conditions. COVID-19 was reported to exacerbate LUTS and cause severe urogenital symptoms, including COVID-19-associated cystitis. Online counseling became essential to maintain treatment continuity while minimizing direct contact. The recommended treatment for moderate to severe BPH-associated LUTS involved tamsulosin monotherapy or in combination with finasteride, with similar rates of acute urinary retention observed in both approaches. The study emphasized the importance of adhering to WHO and EAU guidelines and the need for clear treatment algorithms in the context of COVID-19.